I will try:
It's ugly and unformatted, but here it is...
SOLOS ENDOSCOPY INC
(Other OTC Issues: SNDY)
March 22, 2012
© 2011 Paragon Financial Limited.
All rights reserved.
Page 1 of 6
Analyst Consensus
Rating1
Contents
About SOLOS ENDOSCOPY INC
Company description not available.
Overview
Sector N/A
Industry N/A
Employees N/A
IPO Year
Key Data
Last Trade $0.01
Price Range (52 week) 0 - 0.03
Avg Volume (13 Week) 31,630,000
Shares Outstanding NA
Mkt Cap $2,710,000
Enterprise Value N/A
Book Value per Share $0.00
Dividend Yield N/A
1. Overview
2. Technical Data
3. Key Ratios
4. Earnings & Analyst
5.6. Financial Statements
7. Company Insiders
8. Disclaimer
Highlights & Recent Developments
Throughout the year, Solos has focused its R & D efforts into the design and development
of new modifications to its endoscopic instrument lines to accommodate
the continual advances in Laparoscopic surgical procedures.
the Company has successfully completed, during the month of February, its Food
and Drug Administration (FDA) Level I Baseline Inspection.
In 2011, Solos Endoscopy consummated agreements, which resulted in the forgiveness
of approximately $300,000 in debt for the Company.
1 Analyst Consensus Rating based on publicly
reported third party data. See disclaimer.
SOLOS ENDOSCOPY INC
(Other OTC Issues: SNDY)
March 22, 2012
© 2011 Paragon Financial Limited.
All rights reserved.
Page 2 of 6
Technical Data
52 Week Low $0.00
52 Week High $0.03
50 Day Moving Average NA
200 Day Moving Average NA
Average Daily Volume (13Wk) 31,630,000
Price Information
Support / Resistance
Type Value Confluence
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
Technical Signals Indicator Signal Strength Direction
Composite Indicator
Short-Term Indicators
Medium-Term Indicators
Long-Term Indicators
Trend Spotter Sell Average Weakest
7 Day Average Directional Indicator Buy Average Weakening
10 - 8 Day Moving Average Hilo Channel Buy Weak Weakening
20 Day Moving Average vs Price Buy Average Weakening
20 - 50 Day MACD Oscillator Buy Average Weakest
20 Day Bollinger Bands Hold Falling
40 Day Commodity Channel Index Buy Minimum Weakening
50 Day Moving Average vs Price Buy Average Weakening
20 - 100 Day MACD Oscillator Buy Maximum Strengthening
50 Day Parabolic Time/Price Buy Average Weakening
60 Day Commodity Channel Index Buy Minimum Weakening
100 Day Moving Average vs Price Buy Strong Weakening
50 - 100 Day MACD Oscillator Buy Average Strengthening
SOLOS ENDOSCOPY INC
(Other OTC Issues: SNDY)
March 22, 2012
© 2011 Paragon Financial Limited.
All rights reserved.
Page 3 of 6
Earnings & Analyst Data
Analyst Recommendation Summary
Current 1 Month Ago 2 Months
Ago
3 Months
Ago
Strong Buy (1.0) 13 14 13 13
Moderate Buy (2.0) 4 4 4 3
Hold (3.0) 10 11 12 12
Moderate Sell (4.0) 0 0 0 0
Strong Sell (5.0) 0 0 0 0
Mean Recommendation 1.9 1.9 2.0 2.0
Current Consensus Moderate Buy
EPS Historical Surprises
Estimates Actual Difference Surprise %
Dividend Payments
Dividend
Amount
Ex-dividend Date Payable
Date
0.2 15-May-12 14-Jun-12
0.04 15-May-12 14-Jun-12
0.2 14-Feb-12 8-Mar-12
0.04 14-Feb-12 8-Mar-12
0.2 15-Nov-11 8-Dec-11
0.04 15-Nov-11 8-Dec-11
0.032 16-Aug-11 8-Sep-11
0.16 17-May-11 9-Jun-11
0.032 17-May-11 9-Jun-11
0.16 15-Feb-11 10-Mar-11
0.032 15-Feb-11 10-Mar-11
0.16 16-Nov-10 9-Dec-10
0.032 16-Nov-10 9-Dec-10
0.13 17-Aug-10 9-Sep-10
0.13 17-Aug-10 9-Sep-10
0.13 17-Aug-10 9-Sep-10
0.13 17-Aug-10 9-Sep-10
0.13 17-Aug-10 9-Sep-10
0.026 17-Aug-10 9-Sep-10
0.13 17-Aug-10 9-Sep-10
0.13 18-May-10 10-Jun-10
0.026 18-May-10 10-Jun-10
0.13 16-Feb-10 11-Mar-10
EPS Estimates
# of Ests. Mean Est. High Est. Low Est.
Analyst Upgrades & Downgrades
0 0 0 0 0
0-Jan-00 0 0 0 0
0-Jan-00 0 0 0 0
-- -- -- -- --
-- -- -- -- --
-- -- -- -- --
-- -- -- -- --
-- -- -- -- --
-- -- -- -- --
-- -- -- -- --
-- -- -- -- --
SOLOS ENDOSCOPY INC
(Other OTC Issues: SNDY)
March 22, 2012
© 2011 Paragon Financial Limited.
All rights reserved.
Page 4 of 6
Income Statement Annual Quarterly
Period Ending
Total Revenue -- -- -- -- -- -- --
Cost of Revenue -- -- -- -- -- -- --
Gross Income -- -- -- -- -- -- --
Research and Development -- -- -- -- -- -- --
Selling General and Administrative -- -- -- -- -- -- --
Non Recurring -- -- -- -- -- -- --
Others -- -- -- -- -- -- --
Total Operating Expenses -- -- -- -- -- -- --
Operating Income or Loss -- -- -- -- -- -- --
Total Other Income(Expenses) Net -- -- -- -- -- -- --
Earnings Before Interest And Taxes -- -- -- -- -- -- --
Interest Expense -- -- -- -- -- -- --
Income Tax Expense -- -- -- -- -- -- --
Net Income From Continuing Ops -- -- -- -- -- -- --
Other Items not from Continuing Operations -- -- -- -- -- -- --
Net Income attributable to the Company -- -- -- -- -- -- --
Preferred Stock And Other Adjustments -- -- -- -- -- -- --
Net Income Applicable To Common Shares -- -- -- -- -- -- --
Cash Flow Statement Annual Quarterly
Period Ending
Net Income -- -- -- -- -- -- --
Operating Activities
Depreciation -- -- -- -- -- -- --
Adjustments To Net Income -- -- -- -- -- -- --
Changes In Accounts Receivables -- -- -- -- -- -- --
Changes In Liabilities -- -- -- -- -- -- --
Changes In Inventories -- -- -- -- -- -- --
Changes In Other Operating Activities -- -- -- -- -- -- --
Total Cash Flow From Operating Activities -- -- -- -- -- -- --
Investing Activities
Capital Expenditures -- -- -- -- -- -- --
Investments -- -- -- -- -- -- --
Other Cash flows from Investing Activities -- -- -- -- -- -- --
Total Cash Flows From Investing Activities -- -- -- -- -- -- --
Financing Activities
Dividends Paid -- -- -- -- -- -- --
Sale Purchase of Stock -- -- -- -- -- -- --
Net Borrowings -- -- -- -- -- -- --
Other Cash Flows from Financing Activities -- -- -- -- -- -- --
Total Cash Flows From Financing Activities -- -- -- -- -- -- --
Effect Of Exchange Rate Changes -- -- -- -- -- -- --
Other Liabilities -- -- -- -- -- -- --
SOLOS ENDOSCOPY INC
(Other OTC Issues: SNDY)
March 22, 2012
© 2011 Paragon Financial Limited.
All rights reserved.
Page 5 of 6
Company Insiders
Company Officers
Basic Compensation Options Options Value
Insider Transactions
Trading Date Name Title Type Shares Traded Price
SOLOS ENDOSCOPY INC
(Other OTC Issues: SNDY)
March 22, 2012
© 2011 Paragon Financial Limited.
All rights reserved.
Page 6 of 6
Disclaimer
This report is provided for general information purposes only. The information contained in this report is not to
be construed as advice and should not be confused as any sort of advice. Information has been obtained from
sources considered to be reliable, but we do not guarantee the information is accurate, correct, complete, or
timely or make any warranties regarding results from its usage. Past performance is not a guarantee of future results.
Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Redistribution
or reproduction is prohibited without written permission.
Paragon Report (hereafter “Paragon”) is owned and operated by Paragon Financial Limited (hereafter “PFL”). Paragon/
PFL is an online financial newsletter focused on coverage of small-cap and large-cap public companies. Paragon/PFL is
not a registered broker dealer or a registered investment advisor. No information accessed through the Paragon/PFL Web
site or this report constitutes a recommendation or solicitation to buy, sell or hold any security in any jurisdiction.
All bullish, bearish, neutral or other analyst ratings are based on publically available third party analyst ratings. Specifically,
both the Analyst Consensus Rating and Current Analyst Consensus Data are directly based on information published
by money.msn.com.
Paragon/PFL receives compensation from third party organizations for advertising services provided in the form of email
newsletters. Paragon/PFL and its affiliates, officers, directors and agents have been compensated for featured company
coverage and therefore information should not be construed as unbiased.
Paragon/PFL and its outside sources use certain data derived from the U.S. Securities and Exchange Commission (SEC)
filings, public information and data compiled by other vendors. The reader should verify all claims and do his/her own research
and due diligence before investing in any securities mentioned. Guests of PFL’s website, www.paragonreport.com,
readers of Paragon/PFL’s distributed reports/releases/advertisements, and other interested parties assume full responsibility
for the accuracy of all SEC filing data, compiled data from other sources including data from the issuing Company,
and are urged to confirm that data with the specific issuing Company. Paragon/PFL will not be liable to any person or
entity for the quality, accuracy, completeness, reliability or timeliness of information in this report, or for any direct, indirect,
consequential, incidental, special or punitive damages that may arise out of the use of information, products or services
from any person or entity including but not limited to lost profits, loss of opportunities, trading losses, and damages that
may result from any incompleteness or inaccuracy in the profiled company information Paragon/PFL and its data vendors
do not assume any responsibility or liability for any investor decision made as a result of accessing fundamental and/or
financial data on any profiled company as a consequence of viewing our materials. Paragon/PFL encourages its readers
and visitors to its website to invest carefully and read the investor information available on the web sites of the Securities
and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at
www.nasd.com. Investors interested in purchasing securities are advised to read the Prospectus, 10K, 10Q, other relevant
public documents in full, request Company financial information and to conduct their own research and due diligence.
Statements made in this release may include projections, made in reliance on the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Paragon/PFL has made every reasonable effort to ensure that the information
and assumptions on which these statements and projections are based are current, reasonable, and complete. However,
a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations
expressed in this release. Paragon/PFL makes these statements and projections in good faith, neither Bedf Paragonrd/
PFL nor its management can guarantee that the transactions will be consummated or that anticipated future results
will be achieved.
AI
